Metropolitan Life Insurance CO Bolt Biotherapeutics, Inc. Transaction History

Metropolitan Life Insurance CO

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2021 Feb 15, 2022	SELL	$4.19 - $13.97 $30,155 - $100,542	-7,197 Closed	0 $0
Q3 2021 Jun 21, 2023	BUY	$11.15 - $18.6 $80,246 - $133,864	7,197 New	7,197 $91,000
Q3 2021 Mar 30, 2023	BUY	$11.15 - $18.6 $31,409 - $52,396	2,817 Added 64.32%	7,197 $91,000
Q3 2021 Nov 15, 2021	BUY	$11.15 - $18.6 $80,246 - $133,864	7,197 New	7,197 $91,000
Q2 2021 Aug 16, 2021	SELL	$15.4 - $31.46 $61 - $125	-4 Closed	0 $0
Q1 2021 Jun 26, 2023	BUY	$25.86 - $39.93 $113,266 - $174,893	4,380 New	4,380 $144 Million
Q1 2021 Mar 30, 2023	BUY	$25.86 - $39.93 $113,266 - $174,893	4,380 New	4,380 $144,000
Q1 2021 May 14, 2021	BUY	$25.86 - $39.93 $103 - $159	4 New	4 $144,000

23M

Ticker BOLT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 37,641,500
Market Cap $23.3M
Description
Bolt Biotherapeutics, Inc., a clinical-stage biotechnology company, engages in the development of immuno-oncology agents to target tumor cells for elimination by the immune system. The company is developing BDC-1001, a human epidermal growth factor receptor 2 (HER2), which is in Phase I/II clinical trial for the treatment of patients with HER2-e...

Get notified when there are updates to the investment portfolio of Metropolitan Life Insurance CO, based on Form 13F filings with the SEC.

Stay updated on Metropolitan Life Insurance CO with notifications on news.